Table 3.

Patient characteristics by HER2 status following trastuzumab containing primary chemotherapy

HER2 not amplifiedHER2 amplifiedP
n (%)n (%)
817
Race
    Black1 (12.5%)3 (17.7%)
    Spanish/Hispanic2 (25.0%)17.7%
    White5 (62.5%)11 (64.7%)1
Age at diagnosis, y
    Min40 (–)30 (–)
    Median49 (–)50 (–)
    Max67 (–)61 (–)0.777
Histology
    Ductal7 (87.5%)14 (82.3%)
    Other1 (12.5%)3 (17.7%)1
Clinical T stage
    T11 (12.5%)3 (17.7%)
    T23 (37.5%)7 (41.2%)
    T30 (0.0%)5 (29.4%)
    T44 (50.0%)2 (11.8%)0.143
Clinical N stage
    N02 (25.0%)6 (35.3%)
    N12 (25.0%)9 (52.9%)
    N34 (50.0%)2 (11.8%)0.186
Clinical stage
    I0 (0.0%)1 (5.9%)
    II3 (37.5%)9 (52.9%)
    III5 (62.5%)7 (41.2%)0.774
Nuclear grade
    II2 (25.0%)5 (29.4%)
    III6 (75.0%)12 (70.6%)1
LVI
    Positive3 (37.5%)5 (29.4%)
    Negative5 (62.5%)12 (70.6%)1
ER
    Positive2 (25.0%)12 (70.6%)
    Negative6 (75.0%)5 (29.4%)0.081
PR
    Positive2 (25.0%)11 (64.7%)
    Negative6 (75.0%)6 (35.3%)0.097

Abbreviation: LVI, lymphovascular invasion.